Navigation Links
DRAXIS Obtains Final Order for Proposed Arrangement
Date:5/27/2008

Court approves acquisition of DRAXIS by Jubilant

TORONTO, May 27 /PRNewswire-FirstCall/ - DRAXIS Health Inc. ("DRAXIS") (TSX: DAX) (NASDAQ: DRAX) announced today that it has obtained a Final Order from the Quebec Superior Court in connection with the previously announced proposed statutory plan of arrangement under which all of DRAXIS' common shares will be acquired by an indirect wholly-owned subsidiary of Jubilant Organosys Ltd ("Jubilant") for US$6.00 per common share. The arrangement was approved by 99% of the votes cast by holders of DRAXIS' common shares, which was in excess of the 66 2/3% required, at the annual and special meeting of DRAXIS shareholders held May 23, 2008.

The transaction is expected to close shortly. The transaction remains subject to customary closing conditions.

About DRAXIS Health Inc.:

DRAXIS Health, through its wholly owned operating subsidiary, DRAXIS Specialty Pharmaceuticals Inc., provides products in three categories: sterile products, non-sterile products and radiopharmaceuticals. Sterile products include liquid and freeze-dried (lyophilized) injectables plus sterile ointments and creams. Non-sterile products are produced as solid oral and semi-solid dosage forms. Radiopharmaceuticals are used for both therapeutic and diagnostic molecular imaging applications. Pharmaceutical contract manufacturing services are provided through the DRAXIS Pharma division and radiopharmaceuticals are developed, produced, and sold through the DRAXIMAGE division. DRAXIS employs approximately 500 staff in its Montreal facility.
For additional information please visit http://www.draxis.com

Caution Concerning Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and as contemplated under other applicable securities legislation. These statements can be identified by the use of forward-looking terminology such as "may," "will," "expect," "anticipate," "estimate," "continue," "plan," "intend," "believe" or other similar words. These statements discuss future expectations concerning results of operations or financial condition or provide other forward-looking information. Our actual results, performance or achievements could be significantly different from the results expressed in, or implied by, those forward-looking statements. You should not place undue reliance on any forward-looking statement, which speaks only as of the date made.

These statements are not guarantees of future performance. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks, uncertainties and other factors that may cause the actual results or performance of the Company to be materially different from such statements or from any future results or performance implied thereby. Factors that could cause the Company's results or performance to differ materially from a conclusion, forecast or projection in the forward-looking statements include, but are not limited to:

- the potential acquisition of DRAXIS by Jubilant in an all cash

transaction at US$6.00 per outstanding share (the "Acquisition");

- the ability of each of Jubilant and DRAXIS to satisfy all of the

closing conditions to complete the Acquisition;

- the achievement of desired clinical trial results related to DRAXIS'

pipeline products;

- timely regulatory approval of DRAXIS' products;

- the ability to comply with regulatory requirements applicable to the

manufacture and marketing of DRAXIS' products;

- DRAXIS' ability to obtain and enforce effective patents;

- the non-infringement of third party patents or proprietary rights by

DRAXIS and its products;

- factors beyond DRAXIS' control that could cause interruptions in

operations in its single manufacturing facility (including, without

limitation, material equipment breakdowns);

- reimbursement policies related to health care;

- the establishment and maintenance of strategic collaborative and

commercial relationships;

- DRAXIS' dependence on a small number of key customers;

- the disclosure of confidential information by DRAXIS' collaborators,

employees or consultants;

- the preservation of healthy working relationships with DRAXIS' union

and employees;

- DRAXIS' ability to grow the business;

- the fluctuation of DRAXIS' financial results and exchange and interest

rate fluctuations;

- the adaptation to changing technologies;

- the loss of key personnel;

- the avoidance of product liability claims;

- the loss incurred if current lawsuits against DRAXIS succeed;

- the volatility of the price of DRAXIS' common shares;

- market acceptance of DRAXIS' products;

- factors described under "Outlook" in DRAXIS' MD&A for the most recent

quarter; and

- the risks described in "Item 3. Key Information - Risk Factors" in the

Annual Report Form 20-F filed by DRAXIS with the United States

Securities and Exchange Commission and which is also filed as DRAXIS'

Annual Information Form with Canadian securities regulators.

For additional information with respect to certain of these and other factors, and relating to DRAXIS generally, reference is made to DRAXIS' most recent filings with the United States Securities and Exchange Commission (available on EDGAR at http://www.sec.gov) and the filings made by DRAXIS with Canadian securities regulators (available on SEDAR at http://www.sedar.com). The forward-looking statements contained in this document represent DRAXIS' expectations as at May 26, 2008. Unless otherwise required by applicable securities laws, DRAXIS disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE DRAXIS Health Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Draxis Health selected by Johnson and Johnson Consumer Companies, Inc. for major contract manufacturing relationship
2. DRAXIS to Present at the 2007 UBS Global Life Sciences Conference
3. DRAXIS Health Inc. Announces Retirement of Dr. Martin Barkin as President and Chief Executive Officer
4. DRAXIS Names GE Healthcare as Exclusive Distributor of DRAXIMAGE(R) Sestamibi in USA
5. DRAXIS Announces Application for Normal Course Issuer Bid
6. DRAXIS Share Buyback Approved by TSX
7. DRAXIS to Report Fourth Quarter and Year End 2007 Results on February 7th
8. DRAXIS Health Reports Fourth Quarter and Year End Results
9. DRAXIS Responds to Trading
10. Jubilant to acquire Draxis Health
11. DRAXIS Obtains Interim Order for Proposed Arrangement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... ... (IT) solutions and digital consulting services to the federal government, has been awarded ... Delivery / Indefinite Quantity (ID/IQ) contract in support of the U.S. Army Program ...
(Date:5/3/2016)... ... May 03, 2016 , ... Branches, Inc. is proud to ... Climb children and youth programs in South Miami. Macy’s is a wonderful community partner ... Grow Program provides afterschool tutoring, mentoring, enrichment and academic support to elementary students 5 ...
(Date:5/3/2016)... ... 03, 2016 , ... LunchSkins is changing the future of ocean ... single-use, throw away plastic baggies. The mission-driven bags give back to global leaders in ... LunchSkins mission is all about reducing global plastic waste and we’ve teamed ...
(Date:5/3/2016)... ... May 03, 2016 , ... The ... issued by the Office of the National Coordinator for Health IT (ONC) with ... action when necessary, including suspending and terminating certifications issued to Complete EHRs and ...
(Date:5/2/2016)... ... May 02, 2016 , ... ProElectric Cartoon is a package of 30 ... choose from a variety of electric styles including zap, sizzles, and more. Easily alter ... dof blur, three dimensional rotation, and much more. ProElectric Cartoon’s simplistic style makes it ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 28, 2016  While Abbott,s announced purchase of ... valve repair and stent business, healthcare research firm ... more firmly into patient monitoring.  Kalorama said that ... device areas, with double-digit growth expected the next ... Advanced Remote Patient Monitoring . Abbott Laboratories ...
(Date:4/28/2016)...  The blood testing market in China ... Information and The Freedonia Group in a recent report.  ... The healthcare research firm said that China ... stations and in improving testing at the provincial level.  ... Blood Testing Market in China , which ...
(Date:4/28/2016)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ( ... of oral drug delivery systems, announced today that the Company ... Joseph Gunnar & Co. LLC, taking place on ... Nadav Kidron , CEO of Oramed, will present a ...   PIONEERS 2016, presented by Joseph Gunnar ...
Breaking Medicine Technology: